# Pegtibatinase As an Enzyme Therapy for Patients with Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency (COMPOSE)

> **NCT03406611** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Travere Therapeutics, Inc.** · enrollment: 32 (estimated)

## Conditions studied

- Homocystinuria

## Interventions

- **DRUG:** Pegtibatinase
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03406611
- **Lead sponsor:** Travere Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-01-22
- **Primary completion:** 2026-06
- **Final completion:** 2026-12
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2024-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03406611

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03406611, "Pegtibatinase As an Enzyme Therapy for Patients with Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency (COMPOSE)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03406611. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*